Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00699556 · ClinicalTrials.gov registry record · Phase 2

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

A Phase 2 study of Alcohol Drinking, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
1
Study location

NCT00699556 is a Phase 2 study of Alcohol Drinking that has completed, run by Yale University. The registered enrollment target is 22 participants, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00699556, a Phase 2 study of Alcohol Drinking, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This study examines the effect of combined nicotine replacement therapy (transdermal patch + nasal spray vs. transdermal patch + placebo nasal spray) on reactivity to alcohol and self-administration behavior.

Conditions Studied

Interventions

  • DRUG 21mg transdermal nicotine patch (Nicoderm CQ)
  • DRUG 1mg nicotine nasal spray
  • DRUG placebo nasal spray

Study Locations (1)

Connecticut

  • Connecticut Mental Health Center & Yale-New Haven Hospital - New Haven

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2006-01
Est. Completion 2016-11
Phase Phase 2

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT00699556

The ClinicalTrials.gov registry entry for NCT00699556 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 630-participant average among 85 other Alcohol Drinking trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Drinking appearing as the primary indexed condition, and to 3 interventions - of which 21mg transdermal nicotine patch (Nicoderm CQ) is the first listed.

NCT00699556 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00699556 about?

NCT00699556 is a clinical study titled "Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy". This study examines the effect of combined nicotine replacement therapy (transdermal patch + nasal spray vs. transdermal patch + placebo nasal spray) on reactivity to alcohol and self-administration behavior.

What is the current status of trial NCT00699556?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-01. Estimated completion is 2016-11.

What conditions does trial NCT00699556 study?

This clinical trial studies the following conditions: Alcohol Drinking.

What interventions are being tested in trial NCT00699556?

The interventions under investigation include: 21mg transdermal nicotine patch (Nicoderm CQ) (DRUG), 1mg nicotine nasal spray (DRUG), placebo nasal spray (DRUG).

Who is sponsoring clinical trial NCT00699556?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00699556 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Drinking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.